BACKGROUND: The p160 steroid receptor coactivator (SRC) family is critical to the transcriptional activation function of nuclear hormone receptors. A key member of this family is SRC-3, initially found to be amplified and expressed in breast cancer it has subsequent been shown to be expressed in malignant disease arising from a wide range of other organs. An understanding of the potential role of SRC-3 in the pathogenesis and its possible prognostic role in a broad range of tumours will improve our general understanding of carcinogenesis as well as potentially leading to a new prognostic marker as well as new therapeutic targets. METHODS: Relevant papers were identified by searching the PubMed and MEDLINE databases for article published until 28th February 2009. Only articles published in English were considered. The search terms included "SRC-3", "AIB1" in association with the following terms: "human", "cancer" and "malignant disease". The search focused on malignant disease arising outside of the mammary gland. Full articles were obtained and references were checked for additional material when appropriate. RESULTS: SRC-3 is amplified and expressed in a wide spectrum of human malignant diseases and appears to be a potential prognostic marker in a number of different tumours. CONCLUSION: SRC-3 appears to be implicated in the possible risk of developing prostate and ovarian cancer. Its presence appears to be a marker of aggressive disease. Further research is required to determine its predictive and prognostic utility given the relative paucity of studies for each specific malignant disease. Copyright (c) 2009. Published by Elsevier Ltd.
BACKGROUND: The p160 steroid receptor coactivator (SRC) family is critical to the transcriptional activation function of nuclear hormone receptors. A key member of this family is SRC-3, initially found to be amplified and expressed in breast cancer it has subsequent been shown to be expressed in malignant disease arising from a wide range of other organs. An understanding of the potential role of SRC-3 in the pathogenesis and its possible prognostic role in a broad range of tumours will improve our general understanding of carcinogenesis as well as potentially leading to a new prognostic marker as well as new therapeutic targets. METHODS: Relevant papers were identified by searching the PubMed and MEDLINE databases for article published until 28th February 2009. Only articles published in English were considered. The search terms included "SRC-3", "AIB1" in association with the following terms: "human", "cancer" and "malignant disease". The search focused on malignant disease arising outside of the mammary gland. Full articles were obtained and references were checked for additional material when appropriate. RESULTS:SRC-3 is amplified and expressed in a wide spectrum of humanmalignant diseases and appears to be a potential prognostic marker in a number of different tumours. CONCLUSION:SRC-3 appears to be implicated in the possible risk of developing prostate and ovarian cancer. Its presence appears to be a marker of aggressive disease. Further research is required to determine its predictive and prognostic utility given the relative paucity of studies for each specific malignant disease. Copyright (c) 2009. Published by Elsevier Ltd.
Authors: Jean C-Y Tien; Zhaoliang Liu; Lan Liao; Fen Wang; Yixiang Xu; Ye-Lin Wu; Niya Zhou; Michael Ittmann; Jianming Xu Journal: Cancer Res Date: 2013-05-06 Impact factor: 12.701
Authors: Rebecca E Nakles; Maddalena Tilli Shiffert; Edgar S Díaz-Cruz; M Carla Cabrera; Maram Alotaiby; Anne M Miermont; Anna T Riegel; Priscilla A Furth Journal: Mol Endocrinol Date: 2011-02-03
Authors: Deri Morgan; Kiersten L Berggren; Colby D Spiess; Hannah M Smith; Ajay Tejwani; Scott J Weir; Christopher E Lominska; Sufi M Thomas; Gregory N Gan Journal: Mol Carcinog Date: 2021-09-24 Impact factor: 4.784
Authors: C Palmieri; O Gojis; B Rudraraju; C Stamp-Vincent; D Wilson; S Langdon; C Gourley; D Faratian Journal: Br J Cancer Date: 2013-05-07 Impact factor: 7.640